Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vijaya Knight has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pediatric immunology laboratory evaluation

    by Jonathan P. Lim, Jordan K. Abbott, Vijaya Knight

    Purpose of review: Laboratory evaluation of the immune system is an essential component of diagnostic workup for suspected immune disorders in pediatric patients. Because the immune system evolves rapidly across infancy and childhood, and age-specific reference ranges are limited for many assays, interpretation of immune laboratory results requires careful attention to developmental stage and clinical context. Recent findings: Advances in pediatric immunology have improved understanding of normal, age-appropriate immune development. Consequently, there is growing recognition of the limitations of standard laboratory assays in children and the need for age-specific reference ranges. Developing and applying pediatric reference intervals remains challenging because of assay limitations, sample constraints, and biologic variability across patient populations, issues that are particularly important when interpreting quantitative and functional immune assays. Summary: Accurate diagnosis of immune disorders in children depends on integrating clinical history, physical examination, laboratory trends, and developmental stage. Abnormal laboratory values may reflect normal maturation, benign variation, or transient effects of external factors such as infection rather than true disease. Conversely, reassuring results may still obscure clinically significant immune dysfunction if interpreted in isolation. A structured, age-aware approach to immune testing helps avoid misdiagnosis, supports timely recognition of true immunologic disease, and guides appropriate intervention.

  • Reply

    by Vijaya Knight, Lusia Sepiashvili

  • Reply

    by Vijaya Knight, Lusia Sepiashvili

  • Open Access

    Longitudinal monitoring of class‐switched memory‐B cell proportions identifies plausible germinal center failure in patients with suspected immune disorders

    by Vijaya Knight, Olivia Starich, Cullen M. Dutmer, Jordan K. Abbott

    A reduced proportion of peripheral class‐switched memory B cells (CSM‐B cells) is presumed to indicate ineffective germinal activity. The extent that this finding corresponds to a plausible germinal center failure pathophysiology in patients not diagnosed with CVID or hyper IgM syndrome is not known. We asked if patients with low CSM‐B cells are more likely to demonstrate failure to produce serum IgA and IgG than counterparts with nonreduced class‐switched memory B cell levels, regardless of diagnosis. Patients with low CSM‐B cell levels regardless of diagnosis were retrospectively compared with their counterparts without CSM‐B cell reductions for demographics and serum immunoglobulin levels. Patients were further divided based on whether CSM‐B cell levels remained low over time or fluctuated, and these groups were compared for serum immunoglobulin levels and diagnoses. Of 305 patients, those with CSM‐B cell (n = 50) reductions were more likely to have low serum IgA and IgG than those without reductions. Of the 78 patients in whom CSM‐B cells were measured repeatedly over time, 21 patients had low CSM‐B cell levels, but this finding was persistent in only 10. Patients with persistent CSM‐B cell reductions universally had severe serum IgA and IgG deficiencies and patients with transient CSM‐B cell reduction often did not. These two groups contained divergent diagnoses and likely represent separate pathophysiologic groups. Quantifying CSM‐B cells as a percentage of CD27+ B cells repeatedly over time is a robust approach to identifying patients with a plausible germinal center failure endotype.


  • Alternative assays for identifying the inciting antigen in hypersensitivity pneumonitis

    by Rebecca L. O’bRien, Vijaya Knight, Ronald J. Harbeck, Evans R. Fernández Pérez

  • Open Access

    Ultrasound-Guided Injections of HYADD4 for Knee Osteoarthritis Improves Pain and Functional Outcomes at 3, 6, and 12 Months without Changes in Measured Synovial Fluid, Serum Collagen Biomarkers, or Most Synovial Fluid Biomarker Proteins at 3 Months

    by Richard T. Meehan, Mary T. Gill, Eric D. Hoffman, Claire M. Coeshott, Manuel D. Galvan, Molly L. Wolf, Isabelle A. Amigues, Liudmila M. Kastsianok, Elizabeth A. Regan, James L. Crooks, et al.

    Background: Prior studies have demonstrated improved efficacy when intra-articular (IA) therapeutics are injected using ultrasound (US) guidance. The aim of this study was to determine if clinical improvement in pain and function after IA hyaluronic acid injections using US is associated with changes in SF volumes and biomarker proteins at 3 months. Methods: 49 subjects with symptomatic knee OA, BMI < 40, and KL radiographic grade II or III participated. Subjects with adequate aspirated synovial fluid (SF) volumes received two US-guided IA-HA injections of HYADD4 (24 mg/3 mL) 7 days apart. Clinical evaluations at 3, 6, and 12 months included WOMAC, VAS, PCS scores, 6 MWD, and US-measured SF depth. SF and blood were collected at 3 months and analyzed for four serum OA biomarkers and fifteen SF proteins. Results: Statistical differences were observed at 3, 6, and 12 months compared to baseline values, with improvements at 12 months for WOMAC scores (50%), VAS (54%), and PCS scores (24%). MMP10 levels were lower at 3 months without changes in SF volumes, serum levels of C2C, COMP, HA, CPII, or SF levels of IL-1 ra, IL-4, 6, 7, 8, 15, 18, ILGFBP-1, 3, and MMP 1, 2, 3, 8, 9. Baseline clinical features or SF biomarker protein levels did not predict responsiveness at 3 months. Conclusions: Clinical improvements were observed at 12 months using US needle guidance for IA HA, whereas only one SF protein biomarker protein was different at 3 months. Larger studies are needed to identify which SF biomarkers will predict which individual OA patients will receive the greatest benefit from IA therapeutics.


  • Open Access

    COVID-19 Serology Control Panel Using the Dried-Tube Specimen Method

    by William J. Windsor, Vijaya Knight, Patricia A. Merkel, Molly M. Lamb, Heidi R. Tucker, Kyle Carson, Kelly M. Howard, Jennifer L. Yates, Mario L. Santiago, Mary K. McCarthy, et al.

    The dried-tube specimen (DTS) procedure was used to develop the COVID-19 serology control panel (CSCP). The DTS offers the benefit of shipping materials without a cold chain, allowing for greater access without deterioration of material integrity. Samples in the panel were sourced from COVID-19 convalescent persons from March to May 2020. The immunoglobulin subtypes (total Ig, IgM, and IgG) and their respective reactivity to severe acute respiratory syndrome coronavirus 2 nucleocapsid, spike, and receptor-binding domain antigens of the samples were delineated and compared with the WHO International Standard to elucidate the exact binding antibody units of each CSCP sample and ensure the CSCP provides adequate reactivity for different types of serological test platforms. We distribute the CSCP as a kit with five coded tubes to laboratories around the world to be used to compare test kits for external quality assurance, for harmonizing laboratory testing, and for use as training materials for laboratory workers.


  • Immunodeficiency and Autoantibodies to Cytokines

    by Vijaya Knight

    Background: Anti-cytokine autoantibodies (AAbs) associated with an infectious phenotype are now included along with anti-complement AAbs and somatic pathogenic gene variants as a distinct category termed ‘phenocopies of primary immunodeficiencies’ in the classification of inborn errors of immunity. Anti-cytokine AAbs target specific cytokine pathways, leading to inordinate susceptibility to specific organisms, generally in the setting of immunocompetence.Content: Anti-cytokine AAbs are detected in the majority of healthy individuals and may play a regulatory role in limiting exaggerated responses to cytokines. While it is not well understood why some individuals with anti-cytokine AAbs develop increased susceptibility to organisms of low pathogenicity and others do not, it is likely that genetics and environment play a role. To date, AAbs to interferon gamma (IFNγ), interferon alpha (IFNα), interleukins-17 and 22 (IL-17/IL-22), interleukin-6 and granulocyte macrophage colony stimulating factor (GM-CSF) and their association with increased susceptibility to nontuberculous mycobacteria and other intracellular organisms, viral infections, Candida albicans, Staphylococcus aureus and other pyogenic organisms, and fungal infections respectively, have been described. The clinical phenotype of these patients is very similar to that of individuals with pathogenic gene variants in the specific cytokine pathway that the autoantibody targets, hence the term ‘phenocopy.’ Recognition of anti-cytokine AAbs as a distinct cause of immunodeficiency or immune dysregulation is important for appropriate management of such patients.Summary: Understanding the roles that anti-cytokine AAbs play in health and disease continues to be a fascinating area of research. Evaluating generally immunocompetent individuals who present with chronic, treatment refractory, or unusual infections for anti-cytokine AAbs is critical as it may direct therapy and disease management.